ATAI - Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation | Benzinga
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants.
A DMT formulation, VLS-01 works as a partial agonist of the 5-HT 1A/2A/2C receptors, with an intrinsically short duration of psychedelic effect and a half-life of less than 10 minutes.
As clinical evidence suggests DMT’s IV administration provides rapid-acting antidepressant effects in Major Depressive Disorder (MDD) patients, atai’s proprietary OTF formulation aims to eliminate the need for injectable administration, provide improved pharmacokinetics (PK) and a psychedelic effect lasting 45 minutes, allowing for an enhanced 2-hour ...